Connect with us
  • Elysium


Daily News Update: Monday, 24 June



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Potential targets for prevention and early identification of psychotic disorders

A new study by the Centre for Addiction and Mental Health (CAMH) has found that nearly 75% of young Ontarians with a psychotic disorder had at least one mental health service visit within the three years prior to their first diagnosis of the disorder.

The retrospective cohort study—one of the largest of its kind—suggests that youth with a psychotic disorder are nearly four times as likely to have a previous mental health-related hospital admission, twice as likely to have a mental health-related emergency department visit, and more likely to have a past diagnosis of substance use disorder compared to youth diagnosed with a mood disorder.

Evidence tying cerebral small-vessel disease to Alzheimer’s, dementia

Research led by in part by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) finds that the most common cerebral small-vessel disease feature seen in brain magnetic resonance imaging is a primary vascular factor associated with dementia risk. Results of the major international study emphasize the significance of that feature, known as white matter hyperintensity (WMH) burden, in preventive strategies for dementia.

$2.4 million grant to study link between circadian clock and cluster headaches

The link between severe headache disorders headaches and the body’s circadian clock in pain timing and thresholds will be studied with a $2.4 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to UTHealth Houston researchers. The study builds on earlier research by Burish and Yoo which revealed that both cluster headache and migraine are strongly linked to the internal clock that regulates body processes known as the circadian system.

Company and financial neuro-rehab news

Advancing how scientists can model the human brain

For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announced the launch of ioAstrocytes – a new addition to bit.bio’s ioCells portfolio which creates a toolkit for disease research that addresses the challenges of data reproducibility and enables accelerated therapeutic development.

Anti-Seizure activity in epilepsy models

Trevena has preclinical data from two separate research collaborations examining the cellular mechanism of analgesic effects of TRV045, a novel S1P1 receptor modulator, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN). The second set of studies was from a separate, ongoing collaboration, with the NIH-supported Epilepsy Therapy Screening Program (ETSP) which studied the use of TRV045 in three different preclinical models examining its potential effects on acute seizure protection and its potential ability to modify seizure development, or epileptogenesis.

Technology news

FDA expands approval of gene therapy for patients with Duchenne Muscular Dystrophy

The FDA has expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals four years of age and older with DMD with a confirmed mutation in the DMD gene. Elevidys was previously approved under accelerated approval for ambulatory individuals four through five years of age with DMD with a confirmed mutation in the DMD gene.